These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22563239)

  • 1. Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns.
    Voight L
    Patient Prefer Adherence; 2012; 6():275-83. PubMed ID: 22563239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
    Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
    Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
    Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis.
    Elmedany SH; Mohamed AE; Galil SMA
    Clin Rheumatol; 2019 Aug; 38(8):2109-2117. PubMed ID: 30915650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
    Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
    Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
    Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos-Remus C; Rovensky J; Alecock E; Woodworth T; Alten R;
    Lancet; 2008 Mar; 371(9617):987-97. PubMed ID: 18358926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab: a review of its use in the management of rheumatoid arthritis.
    Oldfield V; Dhillon S; Plosker GL
    Drugs; 2009; 69(5):609-32. PubMed ID: 19368420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
    Daniel SR; McDermott JD; Le C; Pierce CA; Ziskind MA; Ellis LA
    J Med Econ; 2018 Jul; 21(7):724-731. PubMed ID: 29718743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
    Tanaka E; Inoue E; Hoshi D; Shimizu Y; Kobayashi A; Sugimoto N; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2015 Jul; 25(4):503-13. PubMed ID: 25547018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series.
    Talotta R; Atzeni F; Batticciotto A; Ditto MC; Gerardi MC; Sarzi-Puttini P
    J Med Case Rep; 2018 Jun; 12(1):154. PubMed ID: 29859543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
    Kremer JM; Blanco R; Halland AM; Brzosko M; Burgos-Vargas R; Mela CM; Rowell L; Fleischmann RM
    Clin Exp Rheumatol; 2016; 34(4):625-33. PubMed ID: 27087059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-Term Clinical Outcomes With the Activ-L Lumbar Arthroplasty System.
    Bryant JP; Kolcun JPG; Brusko GD; Wang MY; Garcia R
    Int J Spine Surg; 2020 Oct; 14(5):731-735. PubMed ID: 33077433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition.
    Kostić M; Jovanović S; Tomović M; Milenković MP; Janković SM
    Vojnosanit Pregl; 2014 Feb; 71(2):144-8. PubMed ID: 24665571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
    Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA;
    Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis.
    Bolge SC; Eldridge HM; Lofland JH; Ravin C; Hart PJ; Ingham MP
    Patient Prefer Adherence; 2017; 11():661-669. PubMed ID: 28405158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.
    Saiki O; Uda H
    Rheumatol Int; 2018 Dec; 38(12):2307-2313. PubMed ID: 30206670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.